CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, cilt.15, sa.5, ss.625-632, 2020 (SCI-Expanded)
Background and objectives Although renin-angiotensin-aldosterone system inhibition (RAASi) is a cornerstone in the treatment of children with CKD, it is sometimes discontinued when kidney function declines. We studied the reasons of RAASi discontinuation and associations between RAASi discontinuation and important risk markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD study.